Supply Chain Archives
04/29/2025
Optimizing Cryopreservation for Leukapheresis: Advancing Cell and Gene Therapy Supply Chains
The supply chain for fresh leukapheresis is one of the most complex logistical challenges in cell and gene therapy (CGT). As a critical starting material, leukapheresis must be collected from donors, processed, and transported within a limited time window. These challenges increase variability and risk, ultimately impacting the success of advanced therapies. Alexandre Michaux, Process Development & MSAT Manager at IntegriCell™ , recently presented his work on the development of an automated cryopreservation process for leukapheresis in a Poster Presentation at Advanced Therapies Congress in London.
04/22/2025
Advancing Standardization in Cell and Gene Therapy Supply Chains
The future of cell and gene therapy depends not only on scientific advancements but also on the efficiency and reliability of its supply chain. In a recent panel discussion at Advanced Therapies Congress in London, Mark Flower, VP of Business Development, Cryopreservation at Cryoport Systems, explored the critical need for standardization, the challenges in achieving it, and the opportunities to improve logistics, manufacturing, and delivery systems.
04/18/2025
Transforming Patient Access to CGT: Q&A with Aruna Mor
Aruna Mor, Chief Commercial Officer at Cryoport Systems, recently delivered a powerful keynote at Advanced Therapies Congress in London, shedding light on the complexities of patient access and the critical steps needed to overcome these barriers. We sat down with her to delve deeper into some of the key themes of her keynote, exploring the intersection of science, logistics, supply chain, regulation, and collaboration that will determine the future of Cell and Gene Therapy (CGT).
04/14/2025
Enabling the Outcome Through Enhancing Patient Accessibility
Cell and Gene Therapy (CGT) has emerged as one of the most transformative areas in modern medicine, shaping the future of healthcare and changing the face of next-generation therapeutic approaches. Yet, despite the continued scientific progress, a critical challenge persists in ensuring these therapies are accessible to the patients who need them most. This challenge was the focus of the keynote address at the Advanced Therapies Congress in London, delivered by Aruna Mor, Chief Commercial Officer at Cryoport Systems, where she spoke about to the state of patient access within the field of advanced therapeutics.
03/24/2025
Strengthening Global ATMP Logistics: How Cryoport Systems’ Netherlands Facility Supports Temperature-Controlled Supply Chains
The success of ATMPs depends on more than just scientific breakthroughs, it requires a highly controlled, risk-mitigated supply chain that ensures product integrity from research through commercialization. With cell and gene therapies moving across multiple clinical sites, manufacturing facilities, and regulatory jurisdictions, developers need a logistics partner that can support seamless, temperature-controlled supply chain management at a global scale.
03/21/2025
Strengthening ATMP Development in Europe: How BioServices Centers in France Enable Efficiency and Scalability
As Advanced Therapy Medicinal Product (ATMP) developers progress from early-stage research to late-phase clinical trials and commercialization, biostorage, sample management, and regulatory-compliant logistics become increasingly complex. Efficiently managing these critical components is essential to ensure product integrity, regulatory compliance, and seamless supply chain operations.
03/21/2025
Optimizing ATMP Cryopreservation: How IntegriCell™ Services in Belgium Ensure Cell Viability and Supply Chain Integrity
Cryopreservation is quickly becoming a critical yet often underestimated component of the Advanced Therapy Medicinal Product (ATMP) supply chain. The success of cell-based therapies depends on maintaining cell viability, stability, and consistency, yet variability in cryopreservation methods has compromised therapeutic outcomes.
03/12/2025
Global Experts, Local Presence: Strengthening Europe’s Advanced Therapy Supply Chain
The development and commercialization of Advanced Therapy Medicinal Products (ATMPs) in Europe require a highly coordinated supply chain. From temperature-controlled logistics and biostorage to regulatory compliance, every stage of the ATMP lifecycle depends on precision, reliability, and risk mitigation
03/12/2025
